Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.81 Insider Own35.75% Shs Outstand54.87M Perf Week-6.66%
Market Cap576.44M Forward P/E- EPS next Y-1.93 Insider Trans-0.43% Shs Float43.32M Perf Month11.47%
Income-101.76M PEG- EPS next Q-0.41 Inst Own64.55% Short Float24.52% Perf Quarter-28.45%
Sales0.00M P/S- EPS this Y12.20% Inst Trans-0.30% Short Ratio18.85 Perf Half Y17.12%
Book/sh4.87 P/B1.75 EPS next Y-12.19% ROA-35.25% Short Interest10.62M Perf Year66.02%
Cash/sh4.70 P/C1.82 EPS next 5Y- ROE-38.30% 52W Range4.91 - 16.65 Perf YTD-7.07%
Dividend Est.- P/FCF- EPS past 5Y-22.33% ROI-30.96% 52W High-48.65% Beta1.17
Dividend TTM- Quick Ratio21.31 Sales past 5Y0.00% Gross Margin- 52W Low74.13% ATR (14)0.60
Dividend Ex-Date- Current Ratio21.31 EPS Y/Y TTM17.36% Oper. Margin0.00% RSI (14)37.75 Volatility5.29% 6.82%
Employees100 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.11 Target Price19.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q30.06% Payout- Rel Volume1.13 Prev Close8.80
Sales Surprise- EPS Surprise13.79% Sales Q/Q- EarningsMay 06 AMC Avg Volume563.26K Price8.55
SMA20-6.17% SMA50-19.18% SMA200-8.12% Trades Volume638,719 Change-2.84%
Date Action Analyst Rating Change Price Target Change
Feb-23-24Initiated Cantor Fitzgerald Overweight
Sep-22-23Initiated Wedbush Outperform $8
Mar-23-23Upgrade H.C. Wainwright Neutral → Buy $16
Mar-21-23Upgrade Guggenheim Neutral → Buy $15
Mar-16-23Upgrade Oppenheimer Perform → Outperform $14
Jul-18-22Resumed Oppenheimer Perform
Apr-04-22Upgrade Citigroup Neutral → Buy $7 → $10
Mar-25-22Downgrade H.C. Wainwright Buy → Neutral
Mar-22-22Downgrade Oppenheimer Outperform → Perform
Mar-22-22Downgrade Guggenheim Buy → Neutral
May-06-24 09:54PM
May-03-24 04:30PM
Apr-15-24 04:15PM
Apr-08-24 08:00AM
04:30PM Loading…
Apr-05-24 04:30PM
Apr-04-24 04:30PM
Mar-26-24 09:55AM
Mar-12-24 09:01PM
Mar-11-24 04:05PM
Mar-08-24 05:01PM
Mar-06-24 04:30PM
Mar-05-24 04:30PM
Mar-01-24 04:30PM
Feb-14-24 04:30PM
02:23AM Loading…
Feb-09-24 02:23AM
Feb-08-24 08:50AM
Feb-02-24 04:30PM
Feb-01-24 03:05PM
Jan-31-24 04:30PM
Jan-23-24 08:50AM
Jan-22-24 08:30AM
Jan-09-24 12:31PM
Jan-08-24 08:30AM
Jan-02-24 04:30PM
Dec-11-23 12:00PM
Dec-05-23 09:11AM
Dec-01-23 04:30PM
Nov-09-23 04:30PM
Nov-06-23 05:22PM
04:10PM Loading…
Nov-03-23 04:30PM
Nov-02-23 09:00AM
Oct-21-23 07:30AM
Oct-17-23 04:30PM
Oct-16-23 12:00PM
Oct-06-23 04:30PM
Sep-20-23 04:30PM
Sep-01-23 04:30PM
Aug-30-23 04:30PM
Aug-10-23 04:05PM
Aug-04-23 04:30PM
Jun-26-23 01:04PM
Jun-02-23 04:15PM
May-31-23 04:10PM
May-28-23 09:28AM
May-08-23 04:05PM
May-05-23 04:15PM
Apr-25-23 04:30PM
Apr-18-23 04:15PM
Mar-31-23 08:40AM
Mar-29-23 07:53PM
Mar-16-23 04:05PM
Mar-14-23 04:30PM
Mar-06-23 04:15PM
Feb-03-23 04:30PM
Feb-01-23 04:30PM
Jan-27-23 08:41AM
Jan-09-23 08:00AM
Jan-03-23 04:30PM
Dec-22-22 11:35AM
Dec-21-22 05:48PM
Dec-19-22 08:13AM
Dec-13-22 08:00AM
Nov-08-22 04:10PM
Nov-07-22 04:05PM
Nov-03-22 09:00AM
Oct-22-22 08:36AM
Oct-21-22 12:06PM
Oct-14-22 09:37AM
Oct-13-22 12:51PM
Oct-07-22 04:30PM
Sep-28-22 01:47PM
Sep-22-22 10:50AM
Sep-21-22 06:32PM
Sep-13-22 03:45PM
Sep-07-22 01:31PM
Sep-05-22 10:21AM
Sep-01-22 04:15PM
Aug-25-22 11:53AM
Aug-23-22 01:53PM
Aug-20-22 08:28AM
Aug-16-22 10:09AM
Aug-11-22 04:05PM
Jul-11-22 11:00AM
Jun-02-22 04:10PM
May-17-22 04:10PM
May-15-22 08:06AM
Apr-12-22 04:05PM
Mar-31-22 08:33AM
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chacko JacobPRESIDENT AND CEOMar 06 '24Sale16.2140,000648,380728,544Mar 08 04:20 PM
Chacko JacobPRESIDENT AND CEOFeb 07 '24Sale12.2926,042320,186768,544Feb 08 08:01 PM
Chacko JacobPRESIDENT AND CEOFeb 06 '24Sale12.1213,958169,160794,586Feb 08 08:01 PM
Multani Pratik SChief Medical OfficerDec 15 '23Option Exercise0.0014,042029,091Dec 19 07:42 PM
Chacko JacobPresident and CEODec 15 '23Option Exercise0.0038,6670823,083Dec 19 07:39 PM
Chacko JacobPresident and CEODec 15 '23Sale8.5814,539124,813808,544Dec 19 07:39 PM
Multani Pratik SChief Medical OfficerDec 15 '23Sale8.595,28245,35123,809Dec 19 07:42 PM
Piscitelli DominicChief Financial OfficerDec 15 '23Sale8.585,28245,33883,809Dec 19 07:40 PM
Chacko JacobPresident and CEOJul 11 '23Sale8.015,15641,287780,652Jul 11 09:28 PM
Chacko JacobPresident and CEOJul 10 '23Sale8.0110,50884,212785,808Jul 11 09:28 PM
Chacko JacobPresident and CEOJul 05 '23Sale8.014,33634,711796,316Jul 07 04:35 PM
Chacko JacobPresident and CEOJun 26 '23Sale8.0320,000160,562800,652Jun 28 07:18 PM